Brief: ABVC Biopharma Enters Into Term Sheet To License Global Rights Of CNS Drugs with Indications of MDD and ADHD To AiBtl Biopharma
26/10/2023 14:13
Oct 26 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA ENTERED INTO A TERM SHEET TO LICENSE GLOBAL
RIGHTS OF CNS DRUGS WITH THE INDICATIONS OF MDD AND ADHD TO
AIBTL BIOPHARMA AT THE VALUATION OF $667 MILLION
* ABVC BIOPHARMA INC - POTENTIAL LICENSE WILL COVER LICENSED
PRODUCTS' CLINICAL TRIAL, REGISTRATION, MANUFACTURING, SUPPLY,
AND DISTRIBUTION RIGHTS
Source text for Eikon: ID:nGNXbk52VV
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner